Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17261273 | 1.00 | AVPR1B (0.46) | AVPR1BCYP3A4 | |
| SCHEMBL17261119 | 1.00 | AVPR1B (0.46) | AVPR1BCYP3A4 | |
| SCHEMBL17261091 | 0.94 | AVPR1B (0.41) | AVPR1BCYP3A4 | |
| SCHEMBL17261106 | 0.94 | AVPR1B (0.41) | AVPR1BCYP3A4 | |
| SCHEMBL17261178 | 0.94 | AVPR1B (0.41) | AVPR1BCYP3A4 | |
| SCHEMBL17261042 | 0.94 | AVPR1B (0.45) | AVPR1BCYP3A4 | |
| SCHEMBL17261105 | 0.94 | AVPR1B (0.45) | AVPR1BCYP3A4 | |
| SCHEMBL17292656 | 0.94 | AVPR1B (0.45) | AVPR1BCYP3A4 | |
| SCHEMBL1786572 | 0.94 | AVPR1B (0.48) | AVPR1BCYP3A4 | |
| SCHEMBL1786060 | 0.92 | AVPR1B (0.48) | AVPR1BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143023-B1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | ABBVIE DEUTSCHLAND (DE) | 2018-04-11 | — | — | EP | claimed |
| US-9527856-B2 | Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | claimed |
| US-20150344489-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-03 | — | — | US | claimed |
| EP-3143023-B1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | ABBVIE DEUTSCHLAND (DE) | 2018-04-11 | — | — | EP | disclosed |
| EP-3143023-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-9527856-B2 | Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | disclosed |
| US-20150344489-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-03 | — | — | US | disclosed |
| WO-2015173392-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344489-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.